Biologic drugs to drive pharmaceutical market growth

Publication Date	October 2006
Publisher	Datamonitor
Product Type	Report
Pages	9
ISBN Number	not applicable
Product Code	DAT04218

Price

£895.00
approximately: $1,672 | €1,135

PDF

PRINT £945 ($1,766 | €1,199)

Order above formats by FAX

Summary

Introduction

As patent expiries take their toll on small molecule blockbuster drugs Big Pharma are turning to biologic therapies to drive future growth. Alliances and partnerships will be a key strategy in gaining access to the technology needed to successfully penetrate this market

Scope

An overview of our forecasts for the biologic therapy sales of the leading pharmaceutical companies
Discussion of the leading Big Pharma players operating in this area
A review of the evolution in antibody engineering which is currently driving the growth of this area

Highlights

Biologic therapies will drive the majority of the Big Pharma companies sales growth to 2010, based on our forecasts. Of these therapies monoclonal antibodies will be the key sales drivers.

Reasons to Purchase

Benchmark the presence of the Big Pharma companies in the biologics market place
Assess the key strategies that companies are using to gain access to the necessary technologies

Content

Catalyst
Summary
Methodology
- AnaLYSIS
- The growth of biologics are set to change the pharmaceutical market in the future
- Biologics will drive Big Pharma's ethical sales growth
- A number of key competitive forces are driving the success biological therapies
- Pharma companies are reliant on third parties to successfully penetrate the biologic sector
- Competitive position of big pharma players in biologics sector
- Case study: Roche alliance with Genentech has provided it with a strong foothold in the biologics sector
- Amgen - the one that got away
- Monoclonal antibody therapies are the key growth drivers
- The evolution of antibody engineering technology is fuelling the growth of the monoclonal antibodies sector
- The lifecycle of monoclonal antibody therapies are longer because of the lack of biosimilar competition
Appendix
- Definitions
Further reading
- Datamonitor Consultancy
- Ask the analyst
List of Figures
- Figure 1: Biologics are expected to act as the primary growth driver for the Big Pharma peer set, accounting for approximately 60% of absolute annual sales growth over 2004-10
- Figure 2: Big Pharma ethical drug sales split by Biologics and Non-Biologics revenues illustrates the dominant position expected to be held by Roche in 2010
- Figure 3: Technological exposure of antibody development programs is focused on fully human technologies, April 2005